Cargando…

Implications of early diagnosis of autosomal dominant polycystic kidney disease: A post hoc analysis of the TEMPO 3:4 trial

It is unknown whether early diagnosis of autosomal dominant polycystic kidney disease (ADPKD) can enable earlier management and improve outcomes. We conducted a post hoc analysis of data from the TEMPO 3:4 trial. Subjects were stratified by ADPKD diagnosis at age ≤18 (childhood diagnosis [CD]) or>...

Descripción completa

Detalles Bibliográficos
Autores principales:	Janssens, Peter, Jouret, François, Bammens, Bert, Liebau, Max C., Schaefer, Franz, Dandurand, Ann, Perrone, Ronald D., Müller, Roman-Ulrich, Pao, Christina S., Mekahli, Djalila
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7062834/ https://www.ncbi.nlm.nih.gov/pubmed/32152377 http://dx.doi.org/10.1038/s41598-020-61303-9

Ejemplares similares

Unmet needs and challenges for follow-up and treatment of autosomal dominant polycystic kidney disease: the paediatric perspective
por: De Rechter, Stéphanie, et al.
Publicado: (2018)

Clinicians’ attitude towards family planning and timing of diagnosis in autosomal dominant polycystic kidney disease
por: De Rechter, Stéphanie, et al.
Publicado: (2017)

Standardized 4-point scoring scale of [(18)F]-FDG PET/CT imaging helps in the diagnosis of renal and hepatic cyst infections in patients with autosomal dominant polycystic kidney disease: a validation cohort
por: Demuynck, Selina, et al.
Publicado: (2023)

Apelin is altered in subjects with autosomal dominant polycystic kidney disease and preserved kidney function
por: Janssens, Peter, et al.
Publicado: (2023)

Leukopenia in autosomal dominant polycystic kidney disease: a single-center cohort of kidney transplant candidates with post-transplantation follow-up
por: Schellekens, Pieter, et al.
Publicado: (2023)

The wind of change in the management of autosomal dominant polycystic kidney disease in childhood
por: Gimpel, Charlotte, et al.
Publicado: (2021)

Is Autosomal Dominant Polycystic Kidney Disease Becoming a Pediatric Disorder?
por: De Rechter, Stéphanie, et al.
Publicado: (2017)

Enhanced MCP-1 Release in Early Autosomal Dominant Polycystic Kidney Disease
por: Janssens, Peter, et al.
Publicado: (2021)

Gastrostomy Tube Insertion in Pediatric Patients With Autosomal Recessive Polycystic Kidney Disease (ARPKD): Current Practice
por: Burgmaier, Kathrin, et al.
Publicado: (2018)

Translational research approaches to study pediatric polycystic kidney disease
por: Liebau, Max Christoph, et al.
Publicado: (2021)

Tolvaptan use in children and adolescents with autosomal dominant polycystic kidney disease: rationale and design of a two-part, randomized, double-blind, placebo-controlled trial
por: Schaefer, Franz, et al.
Publicado: (2019)

Polycystic Kidney Disease Drug Development: A Conference Report
por: Liebau, Max C., et al.
Publicado: (2022)

Clinical courses and complications of young adults with Autosomal Recessive Polycystic Kidney Disease (ARPKD)
por: Burgmaier, Kathrin, et al.
Publicado: (2019)

Design of two ongoing clinical trials of tolvaptan in the treatment of pediatric patients with autosomal recessive polycystic kidney disease
por: Mekahli, Djalila, et al.
Publicado: (2023)

International consensus statement on the diagnosis and management of autosomal dominant polycystic kidney disease in children and young people
por: Gimpel, Charlotte, et al.
Publicado: (2019)

Effect of tolvaptan in Japanese patients with autosomal dominant polycystic kidney disease: a post hoc analysis of TEMPO 3:4 and TEMPO Extension Japan
por: Muto, Satoru, et al.
Publicado: (2021)

Polycystic Kidney Disease–Related Disease Burden in Adolescents With Autosomal Dominant Polycystic Kidney Disease: An International Qualitative Study
por: Oberdhan, Dorothee, et al.
Publicado: (2022)

Recent Progress of the ARegPKD Registry Study on Autosomal Recessive Polycystic Kidney Disease
por: Ebner, Kathrin, et al.
Publicado: (2017)

Clinical Characteristics and Courses of Patients With Autosomal Recessive Polycystic Kidney Disease-Mimicking Phenocopies
por: Halawi, Abdul A., et al.
Publicado: (2023)

Multicenter, open-label, extension trial to evaluate the long-term efficacy and safety of early versus delayed treatment with tolvaptan in autosomal dominant polycystic kidney disease: the TEMPO 4:4 Trial
por: Torres, Vicente E, et al.
Publicado: (2018)

Prognostic Enrichment Design in Clinical Trials for Autosomal Dominant Polycystic Kidney Disease: The TEMPO 3:4 Clinical Trial
por: Irazabal, Maria V., et al.
Publicado: (2016)

On Methods for the Measurement of the Apelin Receptor Ligand Apelin
por: Janssens, Peter, et al.
Publicado: (2022)

Systematic review on outcomes used in clinical research on autosomal recessive polycystic kidney disease—are patient-centered outcomes our blind spot?
por: Gimpel, Charlotte, et al.
Publicado: (2021)

Early clinical management of autosomal recessive polycystic kidney disease
por: Liebau, Max Christoph
Publicado: (2021)

Management of autosomal-dominant polycystic kidney disease—state-of-the-art
por: Müller, Roman-Ulrich, et al.
Publicado: (2018)

Diagnostic Algorithm in the Management of Acute Febrile Abdomen in Patients with Autosomal Dominant Polycystic Kidney Disease
por: Neuville, Marie, et al.
Publicado: (2016)

Autosomal dominant polycystic kidney
por: Gudadhe, Rugaved Raghavendra, et al.
Publicado: (2022)

Long-term safety profile of tolvaptan in autosomal dominant polycystic kidney disease patients: TEMPO Extension Japan Trial
por: Muto, Satoru, et al.
Publicado: (2017)

Pain and Obesity in Autosomal Dominant Polycystic Kidney Disease: A Post Hoc Analysis of the Halt Progression of Polycystic Kidney Disease (HALT-PKD) Studies
por: Nowak, Kristen L., et al.
Publicado: (2021)

An update on the use of tolvaptan for autosomal dominant polycystic kidney disease: consensus statement on behalf of the ERA Working Group on Inherited Kidney Disorders, the European Rare Kidney Disease Reference Network and Polycystic Kidney Disease International
por: Müller, Roman-Ulrich, et al.
Publicado: (2021)

Can we further enrich autosomal dominant polycystic kidney disease clinical trials for rapidly progressive patients? Application of the PROPKD score in the TEMPO trial
por: Cornec-Le Gall, Emilie, et al.
Publicado: (2018)

Long-term safety profile of tolvaptan in autosomal dominant polycystic kidney disease patients: TEMPO Extension Japan Trial [Corrigendum]
Publicado: (2018)

Tolerability of Aquaretic-Related Symptoms Following Tolvaptan for Autosomal Dominant Polycystic Kidney Disease: Results From TEMPO 3:4
por: Devuyst, Olivier, et al.
Publicado: (2017)

Cyst Fraction as a Biomarker in Autosomal Dominant Polycystic Kidney Disease
por: Karner, Larina A., et al.
Publicado: (2022)

Severe neurological outcomes after very early bilateral nephrectomies in patients with autosomal recessive polycystic kidney disease (ARPKD)
por: Burgmaier, Kathrin, et al.
Publicado: (2020)

Radiographic Imaging in Autosomal Dominant Polycystic Kidney Disease: A Claims Analysis
por: Sanon Aigbogun, Myrlene, et al.
Publicado: (2021)

Effects of tolvaptan discontinuation in patients with autosomal dominant polycystic kidney disease: a post hoc pooled analysis
por: Lioudis, Michael, et al.
Publicado: (2023)

Practical approaches to the management of autosomal dominant polycystic kidney disease patients in the era of tolvaptan
por: Müller, Roman-Ulrich, et al.
Publicado: (2018)

Autosomal dominant polycystic kidney disease in Colombia
por: Camargo, Jessica T., et al.
Publicado: (2023)

Serum levels of carbohydrate antigen 19-9 do not systematically increase in case of liver cyst infection in patients with autosomal dominant polycystic kidney disease
por: Neuville, Marie F, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_3g2mgu34jli0ehnpor771kbast